Janus Henderson Group PLC Makes New Investment in Candel Therapeutics, Inc. $CADL

Key Points

• Janus Henderson Group acquired 171,978 shares of Candel Therapeutics, worth approximately $845,000, giving it a 0.23% stake. Institutional investors collectively own 13.93% of the company.
• Analyst sentiment is broadly positive: seven analysts rate CADL a Buy, two rate it Hold, and one rates it Sell. The stock has a consensus rating of “Moderate Buy” and an average price target of $18.57.
• CADL opened at $10.50, near its 52-week high of $11.36, while the company reported a quarterly loss of $0.14 per share—better than the expected $0.30 loss. Two insiders also sold shares in June, reducing their holdings.

Janus Henderson Group PLC acquired a new position in Candel Therapeutics, Inc. (NASDAQ:CADL - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 171,978 shares of the company's stock, valued at approximately $845,000. Janus Henderson Group PLC owned approximately 0.23% of Candel Therapeutics as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Invesco Ltd. acquired a new position in shares of Candel Therapeutics during the 1st quarter valued at $59,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Candel Therapeutics by 37.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 16,748 shares of the company's stock valued at $95,000 after purchasing an additional 4,583 shares in the last quarter. Rhumbline Advisers raised its position in Candel Therapeutics by 26.8% in the first quarter. Rhumbline Advisers now owns 33,302 shares of the company's stock valued at $188,000 after purchasing an additional 7,030 shares during the period. Geode Capital Management LLC raised its position in Candel Therapeutics by 31.5% in the second quarter. Geode Capital Management LLC now owns 903,970 shares of the company's stock valued at $4,575,000 after purchasing an additional 216,509 shares during the period. Finally, JPMorgan Chase & Co. raised its position in Candel Therapeutics by 36.9% in the second quarter. JPMorgan Chase & Co. now owns 19,533 shares of the company's stock valued at $99,000 after purchasing an additional 5,270 shares during the period. Hedge funds and other institutional investors own 13.93% of the company's stock.

Analyst Upgrades and Downgrades

CADL has been the subject of several analyst reports. Cantor Fitzgerald started coverage on Candel Therapeutics in a research report on Monday, April 20th. They issued an "overweight" rating for the company. Wall Street Zen raised Candel Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday. Stifel Nicolaus began coverage on Candel Therapeutics in a report on Monday, July 13th. They issued a "buy" rating and a $22.00 price target for the company. Weiss Ratings restated a "sell (d-)" rating on shares of Candel Therapeutics in a report on Friday, July 17th. Finally, Zacks Research raised shares of Candel Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Friday, May 15th. Seven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $18.57.

Candel Therapeutics Stock Down 0.8%

CADL stock opened at $10.50 on Tuesday. The firm has a market cap of $769.34 million, a price-to-earnings ratio of -10.71 and a beta of -0.51. Candel Therapeutics, Inc. has a 1-year low of $4.35 and a 1-year high of $11.36. The firm has a fifty day moving average price of $9.48 and a two-hundred day moving average price of $7.27. The company has a debt-to-equity ratio of 0.34, a current ratio of 28.05 and a quick ratio of 28.05.

Candel Therapeutics (NASDAQ:CADL - Get Free Report) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.30) by $0.16. Research analysts predict that Candel Therapeutics, Inc. will post -0.91 EPS for the current year.

Insider Activity

In other news, insider Francesca Barone sold 23,447 shares of the company's stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $10.06, for a total transaction of $235,876.82. Following the completion of the transaction, the insider directly owned 77,362 shares of the company's stock, valued at approximately $778,261.72. This represents a 23.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CTO Seshu Tyagarajan sold 7,000 shares of the stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $10.02, for a total value of $70,140.00. Following the sale, the chief technology officer owned 83,865 shares in the company, valued at $840,327.30. The trade was a 7.70% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 14.30% of the stock is owned by corporate insiders.

Candel Therapeutics Company Profile

Candel Therapeutics NASDAQ: CADL is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company's lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel's pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.

Want to see what other hedge funds are holding CADL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Candel Therapeutics, Inc. (NASDAQ:CADL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source